{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:38:45Z","timestamp":1760488725762,"version":"build-2065373602"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:p>The role of postoperative radiotherapy (PORT) for non-small cell lung cancer (NSCLC) is still debated. A nonlinear relationship may exist between the number of positive lymph nodes (PLN) and the benefits of PORT. Our study seeks to identify patient subgroups that could benefit from PORT by stratifying them based on PLN counts. We enrolled patients with pathologic N2 NSCLC who underwent surgery and adjuvant chemotherapy between January 2004 and December 2015 from the surveillance, epidemiology, and end results (SEER) database. Overall survival (OS) and lung cancer-specific survival (LCSS) were compared between patients receiving PORT and those not receiving PORT. The restricted cubic spline analysis model was applied to investigate the relationship between PLNs and survival. The Kaplan\u2013Meier method was used to generate survival curves, and the log-rank test was applied to compare survival outcomes between the PORT and non-PORT groups. Cox proportional hazard models were employed to calculate adjusted hazard ratios and their corresponding 95% confidence intervals. A total of 4048 patients were eligible, with a median follow-up time of 103 months. PORT had a negative impact on OS (HR\u2005=\u20051.08, 95% CI = 1.01\u20131.17, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03) and showed no association with LCSS (HR\u2005=\u20051.06, 95% CI = 0.98\u20131.15, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.14). The restricted cubic spline analysis analysis indicated that PLN counts could modify the effects of PORT on survival. Patients were categorized into 3 risk subgroups according to their PLN counts: low-risk (1\u20134 PLNs), moderate-risk (5\u20136 PLNs), and high-risk (over 6 PLNs). In the low-risk subgroup, PORT exhibited an adverse effect on OS (HR\u2005=\u20051.17, 95% CI = 1.00\u20131.28, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.01). Conversely, in the moderate-risk subgroup, PORT improved OS (HR\u2005=\u20050.72, 95% CI = 0.60\u20130.87, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.01). In the high-risk subgroup, PORT had no impact on OS (HR\u2005=\u20051.00, 95% CI = 0.86\u20131.16, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20051.00). Analysis in LCSS showed consistent results. While PORT does not universally improve survival outcomes for all patients with pN2 NSCLC, it improves survival for those with a moderate number of PLNs.<\/jats:p>","DOI":"10.1097\/md.0000000000043367","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:02:10Z","timestamp":1753956130000},"page":"e43367","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Postoperative radiotherapy enhances survival in NSCLC patients with moderate lymph node metastases following surgery: A SEER-based population cohort study"],"prefix":"10.1097","volume":"104","author":[{"given":"Xuyang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi Province, China"},{"name":"Department of Oncology, Shangluo Central Hospital, Shangluo, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-0540","authenticated-orcid":false,"given":"Zeliang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medica College, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shangluo Central Hospital, Shangluo, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shangluo Central Hospital, Shangluo, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shangluo Central Hospital, Shangluo, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medica College, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8525-4178","authenticated-orcid":false,"given":"Xinhan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251014","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.21.01774","article-title":"Indications and parameters around postoperative radiation therapy for lung cancer.","volume":"40","author":"Levy","year":"2022","journal-title":"J Clin Oncol"},{"key":"R2-20251014","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2014.58.5380","article-title":"Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R3-20251014","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial.","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"key":"R4-20251014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"R5-20251014","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2024.02.026","article-title":"In regard to J. Ma et al.","volume":"119","author":"Ma","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20251014","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12885-024-12699-4","article-title":"Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy.","volume":"24","author":"Ma","year":"2024","journal-title":"BMC Cancer"},{"key":"R7-20251014","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/1759-7714.15068","article-title":"Enhanced prediction of postoperative radiotherapy-induced esophagitis in non-small cell lung cancer: dosiomic model development in a real-world cohort and validation in the PORT-C randomized controlled trial.","volume":"14","author":"Ma","year":"2023","journal-title":"Thorac Cancer"},{"key":"R8-20251014","doi-asserted-by":"crossref","first-page":"110315","DOI":"10.1016\/j.radonc.2024.110315","article-title":"The cardiac effects of postoperative radiotherapy in patients with non-small cell lung cancer warrants further evaluation.","volume":"196","author":"Ma","year":"2024","journal-title":"Radiother Oncol"},{"key":"R9-20251014","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/j.jtho.2023.03.007","article-title":"Association of heart base dose with overall survival in patients with NSCLC undergoing postoperative radiotherapy.","volume":"18","author":"Ma","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R10-20251014","doi-asserted-by":"crossref","first-page":"101213","DOI":"10.1016\/j.adro.2023.101213","article-title":"Higher lung and heart doses decrease early and long-term survival, respectively, in patients with non-small cell lung cancer undergoing postoperative radiation.","volume":"8","author":"Ma","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"R11-20251014","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/1759-7714.13908","article-title":"Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results (SEER) database.","volume":"12","author":"Sun","year":"2021","journal-title":"Thorac Cancer"},{"key":"R12-20251014","doi-asserted-by":"crossref","first-page":"110241","DOI":"10.1016\/j.radonc.2024.110241","article-title":"Risk of clinically significant cardiovascular disease associated with postoperative radiotherapy in non-small cell lung cancer patients receiving surgical resection followed by adjuvant chemotherapy: a Korean nationwide cohort study.","volume":"195","author":"Kwon","year":"2024","journal-title":"Radiother Oncol"},{"key":"R13-20251014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.radonc.2022.05.019","article-title":"Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer.","volume":"173","author":"Zarinshenas","year":"2022","journal-title":"Radiother Oncol"},{"key":"R14-20251014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cllc.2022.09.011","article-title":"The value of radiotherapy in patients with resectable stage IIIA non-small-cell lung cancer in the era of individualized treatment: a population-based analysis.","volume":"24","author":"Liu","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"R15-20251014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.radonc.2022.06.017","article-title":"A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer.","volume":"173","author":"Zhang","year":"2022","journal-title":"Radiother Oncol"},{"key":"R16-20251014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jtho.2019.10.019","article-title":"The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer.","volume":"15","author":"Edwards","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R17-20251014","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1378\/chest.10-0859","article-title":"Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial.","volume":"139","author":"Darling","year":"2011","journal-title":"Chest"},{"key":"R18-20251014","first-page":"155","article-title":"Clinical application of machine learning in radiation oncology.","volume":"41","author":"Zeliang","year":"2021","journal-title":"Chin J Radiol Med Prot"},{"key":"R19-20251014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40644-024-00659-x","article-title":"MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study.","volume":"24","author":"Liu","year":"2024","journal-title":"Cancer Imaging"},{"key":"R20-20251014","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/1759-7714.13626","article-title":"Multivariate gene expression-based survival predictor model in esophageal adenocarcinoma.","volume":"11","author":"Zhao","year":"2020","journal-title":"Thorac Cancer"},{"key":"R21-20251014","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/1759-7714.14273","article-title":"Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery \u2013 a propensity score matching study of the surveillance, epidemiology, and end Results database.","volume":"13","author":"Bao","year":"2022","journal-title":"Thorac Cancer"},{"key":"R22-20251014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1510\/icvts.2007.174342","article-title":"Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved.","volume":"7","author":"Matsuguma","year":"2008","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R23-20251014","first-page":"2641","article-title":"Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.","volume":"15","author":"Xu","year":"2018","journal-title":"Oncol Lett"},{"key":"R24-20251014","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/1759-7714.12186","article-title":"Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy.","volume":"6","author":"Hui","year":"2015","journal-title":"Thorac Cancer"},{"key":"R25-20251014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13014-017-0946-1","article-title":"Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number.","volume":"12","author":"Wang","year":"2017","journal-title":"Radiat Oncol"},{"key":"R26-20251014","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1111\/1759-7714.14188","article-title":"Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: a systematic review and meta-analysis.","volume":"12","author":"Yuan","year":"2021","journal-title":"Thorac Cancer"},{"key":"R27-20251014","doi-asserted-by":"crossref","first-page":"5479491","DOI":"10.1155\/2022\/5479491","article-title":"Anlotinib enhances the antitumor activity of high-dose irradiation combined with Anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer.","volume":"2022","author":"Yuan","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"R28-20251014","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1111\/1759-7714.14689","article-title":"Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer.","volume":"13","author":"Yuan","year":"2022","journal-title":"Thorac Cancer"},{"key":"R29-20251014","doi-asserted-by":"crossref","first-page":"1464728","DOI":"10.3389\/fimmu.2024.1464728","article-title":"Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: an analysis across different pathological types, treatment modalities and age.","volume":"15","author":"Miao","year":"2024","journal-title":"Front Immunol"},{"key":"R30-20251014","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.21037\/tlcr-24-109","article-title":"Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups.","volume":"13","author":"Miao","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"R31-20251014","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R32-20251014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40644-024-00707-6","article-title":"Preoperative CT-based radiomic prognostic index to predict the benefit of postoperative radiotherapy in patients with non-small cell lung cancer: a multicenter study.","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"key":"R33-20251014","doi-asserted-by":"crossref","first-page":"108063","DOI":"10.1016\/j.lungcan.2024.108063","article-title":"Impact of locoregional recurrence versus distant metastasis on overall survival in patients with non-small cell lung cancer after surgery: a secondary analysis of PORT-C RCT.","volume":"199","author":"Ma","year":"2024","journal-title":"Lung Cancer"},{"key":"R34-20251014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13014-025-02592-0","article-title":"Postoperative radiotherapy improves disease-free survival of EGFR wild-type pN2 non-squamous-cell non-small-cell lung cancer (Nsq-NSCLC) patients after complete resection: a propensity score matching analysis.","volume":"20","author":"Liu","year":"2025","journal-title":"Radiat Oncol"},{"key":"R35-20251014","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/1759-7714.13749","article-title":"Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.","volume":"12","author":"Yuan","year":"2021","journal-title":"Thorac Cancer"},{"key":"R36-20251014","doi-asserted-by":"crossref","first-page":"e2230704","DOI":"10.1001\/jamanetworkopen.2022.30704","article-title":"Trends in postoperative intensity-modulated radiation therapy use and its association with survival among patients with incompletely resected non-small cell lung cancer.","volume":"5","author":"Yu","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:02:35Z","timestamp":1760461355000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":36,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043367","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"2025-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}